44 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
of the study and is due to start soon in the multiple ascending dose portion. We continue to project having topline data from this important safety … continues to project having topline data from this safety and pharmacokinetics study in H1 2024, that the plan is to initiate Phase 2 enabling activities
8-K
EX-10.1
ALGS
Aligos Therapeutics Inc
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes
8-K
EX-99.1
7egqxrx
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
kr7a0eqpc
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
ksady
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
3uzko56w3v
22 Mar 22
Other Events
8:23am
8-K
EX-99.1
1mg 20rr3
10 Mar 22
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:05pm
8-K
iqlbk wpk
6 Jan 22
Other Events
8:11am
S-3
EX-1.2
o3oja49oh5
4 Nov 21
Shelf registration
4:57pm
8-K
EX-99.1
cwo14 2nfe0
4 Nov 21
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
4:08pm